JP2018511319A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511319A5
JP2018511319A5 JP2017550494A JP2017550494A JP2018511319A5 JP 2018511319 A5 JP2018511319 A5 JP 2018511319A5 JP 2017550494 A JP2017550494 A JP 2017550494A JP 2017550494 A JP2017550494 A JP 2017550494A JP 2018511319 A5 JP2018511319 A5 JP 2018511319A5
Authority
JP
Japan
Prior art keywords
seq
hla
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550494A
Other languages
English (en)
Japanese (ja)
Other versions
JP6843062B2 (ja
JP2018511319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024361 external-priority patent/WO2016160622A2/en
Publication of JP2018511319A publication Critical patent/JP2018511319A/ja
Publication of JP2018511319A5 publication Critical patent/JP2018511319A5/ja
Application granted granted Critical
Publication of JP6843062B2 publication Critical patent/JP6843062B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550494A 2015-03-27 2016-03-25 Car t細胞免疫療法のための新規標的としてのhla−g Expired - Fee Related JP6843062B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139617P 2015-03-27 2015-03-27
US62/139,617 2015-03-27
PCT/US2016/024361 WO2016160622A2 (en) 2015-03-27 2016-03-25 Hla-g as a novel target for car t-cell immunotherapy

Publications (3)

Publication Number Publication Date
JP2018511319A JP2018511319A (ja) 2018-04-26
JP2018511319A5 true JP2018511319A5 (enExample) 2019-05-09
JP6843062B2 JP6843062B2 (ja) 2021-03-17

Family

ID=57006294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550494A Expired - Fee Related JP6843062B2 (ja) 2015-03-27 2016-03-25 Car t細胞免疫療法のための新規標的としてのhla−g

Country Status (8)

Country Link
US (3) US20190119385A1 (enExample)
EP (1) EP3274715A4 (enExample)
JP (1) JP6843062B2 (enExample)
CN (1) CN107533051B (enExample)
AU (1) AU2016243128A1 (enExample)
CA (1) CA2981166A1 (enExample)
IL (1) IL254699A0 (enExample)
WO (1) WO2016160622A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810149VA (en) 2016-06-03 2018-12-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
JP7618192B2 (ja) * 2017-03-28 2025-01-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 移植された組織を拒絶反応から保護するための方法
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) * 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CN109111525B (zh) * 2018-05-24 2021-10-29 卢英 一种hla-g嵌合抗原受体、编码序列和表达载体以及应用
US20210301024A1 (en) * 2018-07-04 2021-09-30 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
JP7429222B2 (ja) * 2018-08-31 2024-02-07 アンヴェクティ エスアー Carの機能を評価する方法
TWI694083B (zh) * 2018-09-17 2020-05-21 中國醫藥大學附設醫院 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CN110903399B (zh) * 2018-09-17 2022-02-01 台湾中国医药大学附设医院 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物
UA129052C2 (uk) 2018-09-27 2025-01-01 Тізона Терап'Ютікс Антитіло проти hla-g
AU2020221324A1 (en) 2019-02-15 2021-09-02 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved CAR constructs
TWI717880B (zh) * 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CN110904024A (zh) * 2019-11-13 2020-03-24 武汉济源高科技有限公司 一种悬浮细胞培养中去除死细胞的方法
BR112022011399A2 (pt) 2019-12-11 2022-08-30 A2 Biotherapeutics Inc Receptor de antígeno quimérico baseado em lilrb1
CN113528448B (zh) * 2020-04-14 2023-01-24 同济大学 一种人胚胎干细胞的构建方法
KR20250140123A (ko) 2020-08-20 2025-09-24 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
MX2023002104A (es) 2020-08-20 2023-07-10 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para egfr.
PE20240819A1 (es) 2020-12-17 2024-04-18 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN118234744A (zh) * 2021-05-26 2024-06-21 得克萨斯大学体系董事会 靶向hla-g阳性癌症的嵌合抗原受体
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
US20250213692A1 (en) * 2022-03-25 2025-07-03 Hk Inno.N Corporation Anti-hla-g chimeric antigen receptor, and use thereof
CN119768507A (zh) * 2022-06-24 2025-04-04 怡诺安有限公司 表达免疫检查点调节剂的免疫细胞及其用途
KR20250139268A (ko) * 2022-11-28 2025-09-23 인벡티스, 인크. 인간화 항-hla-g 키메라 항원 수용체 및 이의 용도
CN116699130B (zh) * 2023-04-17 2025-09-16 中国农业科学院都市农业研究所 一种快速检测猪传染性胃肠炎冠状病毒的乳胶免疫层析试纸条及其制备方法
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0819171A1 (en) * 1995-04-07 1998-01-21 The Regents Of The University Of California Antibodies for the detection of hla-g
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
DE60025022D1 (de) * 1999-09-27 2006-01-26 Clifford L Librach Nachweis von hla-g
KR20050083774A (ko) * 2002-10-16 2005-08-26 유로-셀티크 소시에떼 아노뉨 세포-연관된 ca 125/o772p에 결합하는 항체들 및그것의 용도의 방법들
AU2004219603A1 (en) * 2003-03-11 2004-09-23 Genentech, Inc. Novel compositions and methods for the treatment of immune related disease
CN1312182C (zh) * 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla-g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
CN101358964B (zh) * 2007-07-31 2012-06-20 叶尚勉 含抗hla-g的单克隆抗体的癌症诊断试剂盒及其应用
CN101493462A (zh) * 2008-01-25 2009-07-29 广州天美生物技术有限公司 化学发光免疫分析检测hla-g超敏感方法
CN101520458B (zh) * 2008-02-25 2014-04-16 广州天美生物技术有限公司 金标免疫分析检测hla-g及其抗体的简易方法
EP2443147A1 (en) * 2009-06-18 2012-04-25 Hla-G Technologies Hla-g alpha 1 multimers and pharmaceutical uses thereof
US20120178703A1 (en) * 2009-06-25 2012-07-12 Commisariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
CN101967191A (zh) * 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
FR2967579B1 (fr) * 2010-11-23 2013-11-22 Ets Francais Du Sang Utilisation d'une isoforme d'hla-g comme agent anti-resorption osseuse
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120196285A1 (en) * 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
EP2817330B1 (en) * 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CN103756967B (zh) * 2013-12-31 2018-09-21 卢英 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用

Similar Documents

Publication Publication Date Title
JP2018511319A5 (enExample)
JP2018518151A5 (enExample)
JP7328658B2 (ja) 抗pd-l1/抗4-1bb二重特異性抗体およびその使用
CN112154157B (zh) 抗ror1抗体及其用途
KR102589136B1 (ko) 항-b7-h3 항체 및 그 용도
Fisher et al. Generation and preclinical characterization of an antibody specific for SEMA4D
JP2018524973A5 (enExample)
JP2018518152A5 (enExample)
JP2012012402A5 (enExample)
JP2014527398A5 (enExample)
CA2694990A1 (en) Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
TW201207396A (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP2018520668A5 (enExample)
CN110770252A (zh) 抗p53抗体
CN111620949A (zh) 结合人lag-3的抗体、其制备方法和用途
EP3589652A1 (en) Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
JP2020515286A5 (enExample)
JP7082112B2 (ja) 抗gpr20抗体
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
JPWO2023107558A5 (enExample)
CN109593135A (zh) 抗人pd-l1单克隆抗体及其应用
CN116836291B (zh) 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用
CN119101155A (zh) 一种具有人SIRPα结合活性的单克隆抗体及其应用
TW201800420A (zh) 抗ascl1抗體及使用方法